Antibody-drug conjugates (ADCs) have revolutionized cancer care over the last decade, offering targeted therapies with improved efficacy and reduced toxicity. These agents selectively deliver potent chemotherapeutic agents directly to cancer cells, while causing minimal damage to healthy cells. Success of ADCs is highlighted by multiple regulatory approvals across the U.S., Europe, Japan and China.

Clinical development remains intense with pivotal trials ongoing across a variety of tumors, against different molecular targets, and with various chemotherapy payloads. Many ADCs are targeted against tumors due to their exclusive expression on the tumor cell surface, and/or role in tumor progression. This gives rise to a multitude of descriptive approaches, where different ADCs against the same (e.g., HER2 in breast cancer) or different antigens (e.g., BCMA in blood cancers) can be targeted to multiple kingdoms, offering new ways to be targeted across many tumors. An example of this is the use of different payloads for the same antibody, such as Adcetris (brentuximab vedotin) which is approved to treat various lymphomas, while the same antibody, but with different chemotherapies, can be used to treat hematologic malignancies. Treatment options will certainly expand as a result of these approaches.

Contact Cerner Enviza to learn more about the evolving ADC landscape.

Source: CancerMPact® CancerLandscape, accessed October 1 2022

About Cerner Enviza: Cerner Enviza is a comprehensive and integrated healthcare business and digital health company that helps bring remarkable clarity to healthcare’s most important decisions. For more information on Cerner Enviza, visit www.cernerenviza.com. Copyright © 2022 Oracle and/or its affiliates. All rights reserved.